RxDoctor Payments Data

Jacqueline Poletes, APRN

Family · Sun City Center, FLNPI 1699308874

Payments from drug & device makers

$6,759in general payments, 2019–2025

Across 363 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$700
  • Lilly USA, LLC$592
  • Novo Nordisk$529
  • Amgen$526
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$443
  • Esperion Therapeutics, Inc.$370
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$6,745100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,759 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$325,244
Medicare patients
493
Services billed
7,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide142$165,206
EliquisApixaban98$109,668
OzempicSemaglutide42$74,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$32,621
MyrbetriqMirabegron24$31,651
XareltoRivaroxaban20$26,958
ProliaDenosumab12$21,276
JardianceEmpagliflozin13$21,072
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,562
JanuviaSitagliptin Phosphate15$16,313
Breo ElliptaFluticasone/Vilanterol17$10,107
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,141
Gabapentin213$4,237
Atorvastatin Calcium411$4,204
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$592$165,206142 claims
PfizerEliquis$363$109,66898 claims
Novo NordiskOzempic$529$74,16142 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$176$47,86973 claims
Astellas Pharma US IncMyrbetriq$285$31,65124 claims
Johnson & JohnsonXarelto$106$26,95820 claims
AmgenProlia$526$21,27612 claims
Boehringer IngelheimJardiance$61$21,07213 claims
AstraZenecaBreztri Aerosphere$358$16,56218 claims
MerckJanuvia$122$16,31315 claims
AbbVieSynthroid$700$2,29345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Sun City Center

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →